152 related articles for article (PubMed ID: 33314806)
1. Immune responses against autologous tumor and human papilloma virus in lymph nodes from patients with penile cancer.
Zhang L; Zirakzadeh AA; Rosvall J; Hedlund M; Hu PS; Riklund K; Sherif A; Winqvist O
Investig Clin Urol; 2021 Jan; 62(1):39-46. PubMed ID: 33314806
[TBL] [Abstract][Full Text] [Related]
2. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
[TBL] [Abstract][Full Text] [Related]
3. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.
Aydin AM; Hall M; Bunch BL; Branthoover H; Sannasardo Z; Mackay A; Beatty M; Sarnaik AA; Mullinax JE; Spiess PE; Pilon-Thomas S
Int Immunopharmacol; 2021 May; 94():107481. PubMed ID: 33636562
[TBL] [Abstract][Full Text] [Related]
4. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.
Zurek Munk-Madsen M; Toft L; Kube T; Richter R; Ostergaard L; Søgaard OS; Tolstrup M; Kaufmann AM
Hum Vaccin Immunother; 2018 Apr; 14(4):909-916. PubMed ID: 29172992
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
6. Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types.
Williams OM; Hart KW; Wang EC; Gelder CM
J Virol; 2002 Aug; 76(15):7418-29. PubMed ID: 12097554
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.
Carter JJ; Madeleine MM; Shera K; Schwartz SM; Cushing-Haugen KL; Wipf GC; Porter P; Daling JR; McDougall JK; Galloway DA
Cancer Res; 2001 Mar; 61(5):1934-40. PubMed ID: 11280749
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive T-cell immunophenotyping and next-generation sequencing of human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinomas.
Poropatich K; Fontanarosa J; Swaminathan S; Dittmann D; Chen S; Samant S; Zhang B
J Pathol; 2017 Nov; 243(3):354-365. PubMed ID: 28771750
[TBL] [Abstract][Full Text] [Related]
9. Single-cell cytokine analysis allows detection of cervical T-cell responses against human papillomavirus type 16 L1 in women infected with genital HPV.
Passmore JA; Burch VC; Shephard EG; Marais DJ; Allan B; Kay P; Rose RC; Williamson AL
J Med Virol; 2002 Jun; 67(2):234-40. PubMed ID: 11992584
[TBL] [Abstract][Full Text] [Related]
10. CD8+CD45RA+CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7.
Pilch H; Hoehn H; Schmidt M; Steiner E; Tanner B; Seufert R; Maeurer M
Zentralbl Gynakol; 2002; 124(8-9):406-12. PubMed ID: 12655469
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer.
Riazi Rad F; Ajdary S; Omranipour R; Alimohammadian MH; Hassan ZM
Iran Biomed J; 2015; 19(1):35-44. PubMed ID: 25605488
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes.
Picconi MA; Eiján AM; Distéfano AL; Pueyo S; Alonio LV; Gorostidi S; Teyssié AR; Casabé A
J Med Virol; 2000 May; 61(1):65-9. PubMed ID: 10745234
[TBL] [Abstract][Full Text] [Related]
13. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma.
Gregoire L; Cubilla AL; Reuter VE; Haas GP; Lancaster WD
J Natl Cancer Inst; 1995 Nov; 87(22):1705-9. PubMed ID: 7473819
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
[TBL] [Abstract][Full Text] [Related]
15. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus and penile cancers in Rio de Janeiro, Brazil: HPV typing and clinical features.
Scheiner MA; Campos MM; Ornellas AA; Chin EW; Ornellas MH; Andrada-Serpa MJ
Int Braz J Urol; 2008; 34(4):467-74; discussion 475-6. PubMed ID: 18778498
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
18. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
19. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
20. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
